Cedara breast CAD product gets FDA go ahead

TriMed Staff | | Health Imaging | Screening
Cedara Software Corp., which is a division of Merge Technologies Inc., this week announced that Cedara B-CAD, a Computer Aided Detection (CAD) product for breast ultrasound, has received 510(k) clearance from the US Food & Drug Administration (FDA), said Cedara.

Cedara B-CAD will soon be commercially available in the United States.  B-CAD was developed by Toronto based Medipattern Corporation (TSX-V: MKI), a company focused on medical pattern recognition and brought to market by Cedara Software Corp. through it's Technology Partnership Program.

TriMed Staff

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.